Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial.
Samin GhanbariSepehr GohariTara ReshadmaneshMahsa MahjaniShahram Arsang-JangFaramarz Ismail-BeigiMohsen DadashiHossein ChitiAtieh AsgariHoma TaheriOzra ZolfkhaniHassan AhangarPublished in: Journal of diabetes and metabolic disorders (2024)
The original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials. www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective.
Keyphrases
- ejection fraction
- aortic stenosis
- left ventricular
- clinical trial
- coronary artery disease
- heart failure
- blood pressure
- phase ii
- phase iii
- study protocol
- transcatheter aortic valve replacement
- acute myocardial infarction
- percutaneous coronary intervention
- hypertrophic cardiomyopathy
- cardiac resynchronization therapy
- cardiovascular events
- randomized controlled trial
- type diabetes
- cardiovascular disease
- acute coronary syndrome